1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Patrys Limited
  6. Company
    PAB   AU000000PAB9

PATRYS LIMITED

(PAB)
Delayed Australian Stock Exchange  -  02:10 2022-08-10 am EDT
0.0260 AUD   +8.33%
04:10aPatrys Validates Efficacy of Brain Cancer Drug in Preclinical Animal Study
MT
08/07Patrys Chair to Retire End-August
MT
07/27PATRYS : Appendix 4C - Quarterly - 30 June 2022
PU
SummaryQuotesChartsNewsCalendarCompanyFinancials 
Business Summary
Logo Patrys Limited
Patrys Limited is an Australia-based company, which is engaged in the development of antibody therapies for the treatment of cancer. The Company is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The Company has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. The 3E10 antibody has several unusual biological properties not typically seen in antibodies, such as cancer targeting, blood-brain barrier, cell penetrating and inhibit deoxyribonucleic acid (DNA) damage repair. The Company has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. It also uses the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The Company is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.
Sales per Business
20202021Delta
Biopharmaceutical Research and Development0.77100%1.34100% +73.18%
AUD in Million
Sales per region
20202021Delta
Australia0.77100%1.34100% +73.18%
AUD in Million
Managers
Name Title Age Since
James A. Campbell, Dr. Chief Executive Officer, MD & Director - 2015
Valentina Dubljevic Vice President-Scientific & Clinical Development - -
Stefan Ross Secretary - 2021
Deanne Greenwood, Dr. VP-Business Development & Intellectual Property - 2014
Rebecca Tunstall, Dr. Vice President-Corporate Development - 2022
Members of the board
Name Title Age Since
John Douglas Read Non-Executive Chairman 63 2007
Michael J. Stork Deputy Chairman & Non-Executive Director - -
Suzy Jones Non-Executive Director 55 2011
James A. Campbell, Dr. Chief Executive Officer, MD & Director - 2015
Pamela M. Klein, Dr. Non-Executive Director 59 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 2,055,125,410 1,456,661,963 70.9% 0 0.0% 70.9%
Shareholders
NameEquities%
Mason Stevens Ltd. 188,815,565 9.18%
Dax Marcus Calder 170,709,750 8.30%
Michael J. Stork 98,851,900 4.81%
Macquarie Investment Management Ltd. 98,104,192 4.77%
Raymond Laurence Carrol 50,208,750 2.44%
LGL Trustees Ltd. 47,521,099 2.31%
Kemast Investments Pty Ltd. 36,905,073 1.79%
Marginata Pty Ltd. 31,129,425 1.51%
Mladen Marusic 30,125,250 1.46%
Staffwear Pty Ltd. 27,112,725 1.32%
Company contact information
Patrys Ltd.
100 Albert Road
Level 4
South Melbourne, Victoria (VIC) 3204

Phone : +61.3.9670.3273
Web : http://www.patrys.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Patrys Limited